3-D Matrix is selling its approved hemostatic agent PuraStat® in Europe, Latin America and Southeast Asia and preparing investigational studies for FDA approval. In the United States, 3-D Matrix has successfully completed a pilot study to use PuraMatrix® as a dental bone void filler. In Japan 3-D Matrix is currently completing trials for various clinical applications.
PuraMatrix® is a platform technology that can fulfill numerous clinical indications and therapeutic needs.
PuraMatrix® is currently undergoing clinical trials as a dental bone regenerative therapy. PuraMatrix® Bone Void Filler (BVF) is inserted into bony voids or gaps of the skeletal system (i.e., sinus lift procedures) to resorb and be replaced with bone during ossification. PuraMatrix® BVF could be indicated for use in healthy adults undergoing dental alveolar sinus elevation procedures for dental implants.
PuraMatrix® BVF is a solution of synthetic 16-amino acid polypeptides in sterile water. It polymerizes (self-assembles) to form a high-viscosity gel upon contact with tissue, forming a nanofibrous scaffold suitable for bone ingrowth. It is provided sterile in syringes for single use.